1. Ex vivogene therapy for lysosomal storage disorders: future perspectives
- Author
-
Poletto, Edina, Silva, Andrew Oliveira, Weinlich, Ricardo, Martin, Priscila Keiko Matsumoto, Torres, Davi Coe, Giugliani, Roberto, and Baldo, Guilherme
- Abstract
ABSTRACTIntroductionLysosomal storage disorders (LSD) are a group of monogenic rare diseases caused by pathogenic variants in genes that encode proteins related to lysosomal function. These disorders are good candidates for gene therapy for different reasons: they are monogenic, most of lysosomal proteins are enzymes that can be secreted and cross-correct neighboring cells, and small quantities of these proteins are able to produce clinical benefits in many cases. Ex vivo gene therapy allows for autologous transplant of modified cells from different sources, including stem cells and hematopoietic precursors.Areas coveredHere, we summarize the main gene therapy and genome editing strategies that are currently being used as ex vivo gene therapy approaches for lysosomal disorders, highlighting important characteristics, such as vectors used, strategies, types of cells that are modified and main results in different disorders.Expert opinionClinical trials are already ongoing, and soon approved therapies for LSD based on ex vivo gene therapy approaches should reach the market.
- Published
- 2023
- Full Text
- View/download PDF